Cargando…
Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
BACKGROUND: Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies. CASE SUMMARY: A patient with stage IIIB pleural mesothelioma received second-line...
Autores principales: | Xuan, Tian-Tian, Li, Guang-Yi, Meng, Si-Bo, Wang, Zhan-Mei, Qu, Lin-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403696/ https://www.ncbi.nlm.nih.gov/pubmed/36159517 http://dx.doi.org/10.12998/wjcc.v10.i23.8284 |
Ejemplares similares
-
Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021) -
Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020) -
An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020) -
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
por: Banerji, Shantanu, et al.
Publicado: (2021) -
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)